Why is Talkspace betting on Medicare?

Virtual mental health company Talkspace is looking to crack the Medicare market as the digital health startup approaches profitability.

March 4, 2024 Check out STAT+

Sponsored By

Adobe STAT+ | Medicare is a tricky market for telehealth companies. Why is Talkspace betting on it? Virtual mental health company Talkspace is looking to crack the Medicare market as the digital health startup approaches profitability. By Mario Aguilar In a first, fetal cell organoids generated from amniotic fluid, new study reports Researchers at University College London reported that they had successfully generated fetal cell model organisms from amniotic fluid. By Deborah Balthazar STAT+ | White House touts incremental step in Medicare drug price negotiation: counteroffers The White House on Monday ballyhooed a routine step in Medicare's new program to negotiate the prices of prescription drugs. By Rachel Cohrs Adobe STAT+ | Explaining Change Healthcare and the gravity of its cyberattack STAT spoke with health economist Ben Handel to provide context on Change Healthcare, and why a cyberattack on Change is such a big deal. By Bob Herman STAT+ | Federal regulators, scrambling to keep up with AI in health care, team up with industry to set standards Industry group Coalition for Health AI will have the FDA and at least one other federal agency represented on its board of directors. By Casey Ross Opinion: Missing data is making it difficult for the pharmaceutical industry to help LGBTQ+ people The pharma indusry has seen promising efforts in diversifying clinical trials. That work must also include LGBTQ+ populations. By Paul Shay Alex Hogan/STAT Q&A: Stem cell biologist predicts human embryo models could pave the way to organ transplants Stem cell biologist Jacob Hanna, a 2024 STATUS List member, says embryo models can be handled ethically, and can lead to advances in organ transplantation. By Nicholas St. Fleur STAT+ | 'It's a nightmare': One of the most common children's asthma meds is no longer available, leaving families scrambling When GlaxoSmithKline discontinued Flovent, a widely used asthma drug, families were left searching for a replacement. By Jason Laughlin — Boston Globe

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser